Amyloid-β
β-amyloid peptide; Aβ; Abeta
Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.
All Product Categories
-
Amyloid-β Inhibitors
(481)
View all products
-
Amyloid-β Agonists
(2)
View all products
-
Amyloid-β Antagonists
(5)
View all products
-
Amyloid-β Activators
(5)
View all products
-
Amyloid-β Modulators
(4)
View all products
-
Amyloid-β Chemicals
(7)
View all products
-
Amyloid-β Inducers
(5)
View all products
-
Amyloid-β Degraders
(6)
View all products
-
Amyloid-β Controls
(3)
View all products
-
Amyloid-β Substrate
(1)
View all products
-
Amyloid-β Ligands
(11)
View all products
-
Amyloid-β Related Products (757)
Related Products (757)
-
Antibodies (9)
-
BTA-EG4
0 ImagesCat. No.: HY-153889CAS No.: 921193-28-4BTA-EG4 is a catalase-amyloid interaction inhibitor, which can significantly enhance the neurotoxicity of amyloid peptides in catalase-overexpressing neuronal cells, and can be used in the study of neurodegenerative diseases.
-
β-Amyloid (17-40)
0 ImagesCat. No.: HY-P3275CAS No.: 156790-69-1Synonyms: Aβ(17-40)β-Amyloid (17-40) (Aβ(17-40)) is a fragment of Amyloid-β peptide that has shown neurotoxic activities in SH-SY5Y and IMR-32 cells. β-Amyloid (17-40) can be used for the research of neurological disease.
-
Aβ aggregation-IN-6
0 ImagesCat. No.: HY-123745CAS No.: 439932-74-8Aβ aggregation-IN-6 is an Aβ aggregation inhibitor with ~60-70% inhibition of Aβ17-40 aggregation. Aβ aggregation-IN-6 stabilizes Aβ dimer assembly, binds to Aβ steric-zipper assembly. Aβ aggregation-IN-6 can be used for the research of alzheimer's disease.
-
(Gly22)-Amyloid β-Protein (1-42)
0 ImagesCat. No.: HY-P3845CAS No.: 1802086-23-2(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation.
-
ChE/GSK-3β-IN-1
0 ImagesCat. No.: HY-179496ChE/GSK-3β-IN-1 (compound 18o) is a potent dual ChE/GSK-3β inhibitor. ChE/GSK-3β-IN-1 exhibits dual inhibition of AChE (IC50 = 1.7 μM), butyrylcholinesterase (BChE) (IC50 = 5.3 μM), and GSK-3β (IC50 = 5.7 μM). ChE/GSK-3β-IN-1 inhibits Aβ1-42 self-aggregation. ChE/GSK-3β-IN-1 can be used for Alzheimer’s disease (AD) research.
-
(Rac)-BIIB042
0 ImagesCat. No.: HY-103537CAS No.: 1257395-14-4(Rac)-BIIB042 (Compound 10) is an modulator of γ-Secretase. (Rac)-BIIB042 reduces Amyloid-β 42 level with an EC50 value of 0.39 µM. (Rac)-BIIB042 can be used for the study of Alzheimer's disease.
-
β-Amyloid (10-35), amide
0 ImagesCat. No.: HY-P1567CAS No.: 181427-66-7β-Amyloid (10-35), amide is composed of 26 aa (10-35 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease.
-
GFAP/NF-κB/APOE/NLRP3-IN-1
0 ImagesCat. No.: HY-183796GFAP/NF-κB/APOE/NLRP3-IN-1 is an orally active, blood-brain barrier-permeable multi-target inhibitor with an IC50 of 3.50 nM against Acetylcholinesterase. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits BACE-1 with an IC50 of 14.61 nM. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits Aβ1-42 aggregation with an IC50 of 8.63 μM. GFAP/NF-κB/APOE/NLRP3-IN-1 reduces the levels of GFAP, NLRP3 inflammasome, NF-κB and APOE. GFAP/NF-κB/APOE/NLRP3-IN-1 is applicable for the research of Alzheimer's disease and neuroblastoma.
-
DSS30
0 ImagesCat. No.: HY-147387CAS No.: 883027-32-5DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease.
-
Phytic acid hexalithium
0 ImagesCat. No.: HY-181448Synonyms: Inositol hexaphosphate hexalithium; SNF472 hexalithiumPhytic acid (Inositol hexaphosphate hexalithium) hexalithium is an orally active compound. Phytic acid hexalithium can be derived from the seeds of legumes. Phytic acid is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid hexalithium attenuates Aβ oligomers and upregulates Autophagy protein. Phytic acid hexalithium can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
-
(Mor-Cor)Ag(III)
0 ImagesCat. No.: HY-181178(Mor-Cor)Ag(III) is a blood-brain barrier-penetrant silver(III) corrole complex that penetrates the blood-brain barrier. (Mor-Cor)Ag(III) scavenges reactive oxygen species induced by Aβ42 and disrupts Aβ42 aggregation, attenuating Aβ42-induced neuronal hyperactivity. (Mor-Cor)Ag(III) can be used for the research of Alzheimer's disease.
-
Amyloid Bri Protein (1-23)
0 ImagesCat. No.: HY-P10192CAS No.: 717122-86-6Synonyms: ABri peptide (1-23); ABri23Amyloid Bri Protein (1-23) (ABri peptide (1-23); ABri23) is a physiological 23-amino-acid peptide released from the C-terminus of the type II transmembrane protein Bri2 (ITM2B, Integral Membrane Protein 2B) following cleavage by the furin protease. Amyloid Bri Protein (1-23) interacts with the extracellular Brichos domain of Bri2 during Bri2 biosynthesis. Amyloid Bri Protein (1-23) interacts with amyloid β peptide (Aβ1-40, thereby inhibiting its aggregation and fibril formation. Amyloid Bri Protein (1-23) can be used in studies related to Alzheimer's disease and familial British dementia.
-
YIAD-0205
0 ImagesCat. No.: HY-149430CAS No.: 2446054-34-6YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD).
-
Pellitorine (Standard)
0 ImagesCat. No.: HY-N3097RCAS No.: 18836-52-7Pellitorine (Standard) is the analytical standard of Pellitorine (HY-N3097). Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.
-
β-Amyloid (15-21)
0 ImagesCat. No.: HY-P1521CAS No.: 365537-52-6Synonyms: Beta-Amyloid (15-21)β-amyloid (15-21) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.
-
Aβ-IN-10
0 ImagesCat. No.: HY-169268Aβ-IN-10 (Compound Alz -5) is a bifunctional copper chelator and an inhibitor for beta-amyloid (Aβ), that interacts with Aβ aggregates and reduces the neurotoxicity. Aβ-IN-10 exhibits antioxidant efficacy, reveals moderate cytotoxicity with the presence of CuCl2 in SH-SY5Y and HepG2 with IC50 of 65.5, 31.2 μM. Aβ-IN-10 reduces the increase of cell stiffness caused by Aβ.
-
Amyloid β-Protein (5-42)
0 ImagesCat. No.: HY-P4894CAS No.: 1678415-97-8Amyloid β-Protein (5-42) is aAβ Fragment.
-
Aβ/tau aggregation-IN-4
0 ImagesCat. No.: HY-180843CAS No.: 3105860-83-8Aβ/tau aggregation-IN-4 (Compound D21) is an Aβ/tau aggregation inhibitor. Aβ/tau aggregation-IN-4 promotes the degradation of Aβ40/42 (Aβ40, IC50 = 2.151 μM; Aβ42, IC50 = 3.622 μM). Aβ/tau aggregation-IN-4 shows selective AChE inhibition (IC50: 5.56 μM). Aβ/tau aggregation-IN-4 inhibits MAO-A and MAO-B with IC50s of 0.59 μM and 0.09 μM, respectively. Aβ/tau aggregation-IN-4 suppresses intracellular ROS levels. Aβ/tau aggregation-IN-4 can be used in the research of Alzheimer's disease.
-
EVP-0015962
0 ImagesCat. No.: HY-117521CAS No.: 1447811-26-8EVP-0015962 is an orally active, blood-brain barrier-permeable γ-secretase inhibitor with an IC50 of 3.9 μM. EVP-0015962 alters γ-secretase-mediated cleavage of amyloid precursor protein, reduces Aβ42 production and increases Aβ38 production. EVP-0015962 reduces Aβ aggregates, amyloid plaques and inflammatory markers in the brains of mice, and improves their cognitive impairment. EVP-0015962 can be used for the research of Alzheimer's disease.
